Cureus | 2023 | Şensöz E, Cecen G
Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.
Conflict of interest statement: The authors have declared that no competing interests exist. 16. J Am Acad Orthop Surg. 2015 Sep;23(9):550-7. doi: 10.5435/JAAOS-D-14-00024. Epub 2015 Jul 20. Atypical Femur Fractures Associated With Diphosphonate Use. Balach T, Baldwin PC, Intravia J. Comment in J Am Acad Orthop Surg. 2016 Jan;24(1):e20. doi: 10.5435/JAAOS-D-15-00488. J Am Acad Orthop Surg. 2016 Jan;24(1):e20. Osteoporosis-related fractures create a heavy economic and healthcare burden. Although diphosphonate medications have been successful at decreasing the risk of osteoporotic fragility fractures and have become staples in the treatment of osteoporosis, concerns have been raised about the association of diphosphonate therapy with spontaneous nonvertebral fractures. Diphosphonate fractures are characteristically transverse or slightly oblique in nature and occur in the lateral cortex, or tension side, of the subtrochanteric region of the femur where diffuse cortical thickening and fracture can be observed on radiographs. A multidisciplinary approach incorporating both medical and surgical teams should be used in the case of diphosphonate-associated fractures. Future medical and surgical developments that augment fracture fixation and counteract diphosphonate-associated osteoclast apoptosis may play a role in therapy. Although diphosphonate use has decreased the rate of osteoporosis-related fractures, increased awareness and association with atypical subtrochanteric fractures is an important concern for clinicians to keep in mind. Copyright 2015 by the American Academy of Orthopaedic Surgeons. DOI: 10.5435/JAAOS-D-14-00024
This article has not been linked to a wiki topic yet.
This article has not been linked to a case yet.
This article has not been linked to an atlas yet.